• English
  • Korean
  • Chinese
市場調査レポート - 236838

世界の造影剤市場

Imaging Agents

発行 Global Industry Analysts, Inc.
出版日 ページ情報 英文 343 Pages
価格

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。 PDFのダウンロード・閲覧には Adobe Digital Editions が必要となります。ご購入頂いた場合、同Adobe Digital Editions (ご購入時無償配布)をPCにインストールして頂き、ダウンロードを行ったPC上のみでの閲覧と、1回のプリントアウトが可能となっております。ご不明な点につきましてはお問合せください。

世界の造影剤市場 Imaging Agents
出版日: 2014年09月01日 ページ情報: 英文 343 Pages
概要

当レポートでは、世界の造影剤市場について調査し、米国、カナダ、日本、欧州、アジア太平洋地域、中東、ラテンアメリカの地域別分析、今後の市場の予測、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • 造影剤:概要
    • 市場シナリオ:不況と将来動向
    • 現在および将来分析
    • 地域別分析
    • セグメント別分析
    • 成長促進因子
    • 成長阻害因子
    • 核医学
    • 核医学に用いられるPETおよびSPECT放射性同位体
    • 心臓および癌のための放射性医薬品
    • 癌の発症率上昇
    • 成長を促進する医療費拡大
    • 高齢化 他
  • セグメントレビュー
    • 造影剤
    • 造影剤の人気ブランド
    • X線
    • MRI
    • 超音波
    • 診断用放射性医薬品
    • 免疫抱合体
  • 市場動向と課題
  • 競合
    • 市場構造
    • 市場参入者
    • MRI市場の主要企業
    • 超音波造影剤市場
    • 診断用放射性医薬品
  • 世界の医療用画像市場:概要
    • 医療用画像:臨床診断の環境変化
    • 様々な画像システム別のモダリティ比較
    • 不況の影響下にある医療用画像業界 他
  • 製品概要
  • 技術動向
  • 製品上市/認可/治験
  • 近年の業界活動
  • 主要企業
  • 世界市場見通し

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • ロシア
  • アジア太平洋地域
    • 中国
    • インド
  • 中東
  • ラテンアメリカ
  • その他

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

This report analyzes the worldwide markets for Imaging Agents in US$ by the following Product Segments: Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 52 companies including many key and niche players such as -

Bayer Healthcare Pharmaceuticals
Bracco Diagnostics, Inc.
Daiichi Sankyo Company Limited
Eisai Co., Ltd.
Eli Lilly and Company

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Contrast Media
      • X-Ray Contrast Media
      • Magnetic Resonance Imaging (MRI) Contrast Media
      • Ultrasound Contrast Media
    • Diagnostic Radiopharmaceuticals

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Imaging Agents: A Quick Primer
  • Market Scenario: Recession and the Road Ahead
  • Current and Future Analysis
  • Analysis by Region
    • United States: Holds the Largest Share
    • Developing Countries: Potentially Lucrative Market
  • Analysis by Segment
    • Contrast Media: Giving Way to Contemporary Offshoots
    • Diagnostic Radiopharmaceuticals to Outdo Contrast Media
  • Growth Drivers
  • Growth Inhibitors
  • Nuclear Medicine: A Potential Growth Avenue for Dx Radiopharmaceuticals
  • Select PET and SPECT Radioisotopes Used in Nuclear Medicine
  • Select Cardiology and Oncology Radiopharmaceuticals
  • Rising Incidence of Cancer - A Major Growth Driver
    • World Cancer Statistics - Incidence and Mortality Data
    • Table 1: World Cancer Incidence by Geographic Region (2012): Number of New Cancer Cases Reported in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 2: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
  • Improving Healthcare Expenditure to Foster Growth
    • Table 3: Per-Capita Healthcare Expenditure in Select Regions (2013) (includes corresponding Graph/Chart)
    • Table 4: Top 20 Countries with the Highest Healthcare Spending as a Percentage of GDP: 2012 (includes corresponding Graph/Chart)
    • Table 5: Top 10 Countries with Highest Government Spending on Health Care (includes corresponding Graph/Chart)
    • Table 6: Top 10 Countries with Highest Private Spending on Health Care (includes corresponding Graph/Chart)
  • Ageing Population - A Vital Demography
    • Table 7: Global Population Statistics for the 65+ Age Group (Male & Female) for Major Countries/Regions: 2013E (includes corresponding Graph/Chart)
    • Table 8: Percentage of Population Aged 65 and Above in Europe, US, and Japan (1960-2030) (includes corresponding Graph/Chart)
    • Table 9: Elderly Population (65+ Years) as a Percentage of the Total Population: 2025 (includes corresponding Graph/Chart)
  • A Peek Into Pricing Dynamics
  • A Synoptic Overview
  • Pros & Cons
  • Positive Factors Driving Prices
  • Negative Factors Bearing Down on Prices
  • Reimbursements
  • Europe
  • United States

2. A SEGMENTAL REVIEW

  • Contrast Media
  • Popular Brands of Contrast Agents
  • X-ray Contrast Media
  • MRI Contrast Media
    • Market Scenario
      • List of FDA Approved Gadolinium-Based Contrast Agents (GBCA) for CNS MRI
      • List of EMA Approved Gd Chelated Contrast Agents
  • Ultrasound Contrast Media
    • Market Overview
  • Diagnostic Radiopharmaceuticals
    • Market Overview
    • Commonly Used Diagnostic Radiopharmaceutical Agents
      • Major Isotopes and their Diagnostic Applications
      • List of Select FDA-Approved Diagnostic Radiopharmaceuticals
    • New Imaging Agent for Radiopharmaceutical Scans
  • Immunoconjugates
    • Market Overview

3. MARKET TRENDS & ISSUES

  • Expansion of Molecular Imaging Platform is Key to Future Growth
  • Growing Interest in Image Guided Surgery Offers New Opportunities
  • Fluorescence Optical Imaging - Opens New Avenues
  • Coronary CT Angiography Opens Up Opportunities for Contrast Agents
  • List of Iodine-Containing Contrast Agents for Coronary CT Angiography
  • Targeted Imaging - A Game Changer in the Making
  • Clinical Acceptance of MRI Systems on Rise
  • Nanomaterials Taking the Center Stage
  • Gadolinium Coated Nanoparticles - A Promising Imaging Agent
  • Rise in Use of Gold Nanoparticles in X-Ray Imaging Applications
  • Imaging Agents Make a Welcome Impact in the Field of Alzheimer's Disease
  • List of FDA Approved Alzheimer's Diagnostic Imaging Agents
  • Contrast-Enhanced Tomosynthesis Expands Opportunities
  • Hyperpolarized Gases as Contrast Agents
  • Multi-Modal Imaging: Combating Contrast Medium Inconsistencies
  • Falling Prices Turn on the Heat
  • Ultrasound Contrast Agents in Diagnosis of Kidney Ailments
  • FDA Mandates Black Box Warning Label for Gadolinium-Based MRI Contrast Agents
  • PET: A Prime Growth Driver for Diagnostic Radiopharmaceuticals
  • Innovative Radiotracers to Boost Cardiac Applications for SPECT and PET Modalities
  • Global CVD Stats
    • Table 10: Global Estimated Fatalities by Heart Conditions - Percentage Share Breakdown for Ischemic Heart Disease, Stroke, CVD, and Others (includes corresponding Graph/Chart)
    • Table 11: Projected Fatalities in Low Income Countries by Disease (2015 & 2030): Percentage Share Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart)
    • Table 12: Projected Fatalities in Mid Income Countries by Disease (2015 & 2030): Percentage Share Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart)
    • Table 13: Projected Fatalities in High Income Countries by Disease (2015 & 2030): Percentage Share Breakdown of Number of Deaths for CVD, Cancer, Injury and Others (includes corresponding Graph/Chart)
    • Table 14: Estimated Annual Medical Cost (US$ Billions) for Coronary Heart Disease (2015, 2020 & 2025) (includes corresponding Graph/Chart)
  • Opportunities on Rise for Fluorine-Based Myocardial Perfusion Agents
  • Mobile Devices - Future of Diagnostic Imaging
  • Global Technetium Shortage Eased
  • Unfounded Fears of Radiation Exposure: A Major Concern for Nuclear Diagnostics

4. COMPETITION

  • Market Structure
  • Market Participants
  • Key Players in the MRI Market
  • Ultrasound Imaging Agents Market
  • Diagnostic Radiopharmaceuticals
    • Table 15: Worldwide Imaging Agents Market (2013): Percentage Breakdown of Value Sales for Leading Players - Bayer Schering Pharmaceuticals, Bracco, Covidien/Mallinckrodt, GE Healthcare, and Others (includes corresponding Graph/Chart)
    • Table 16: MRI Contrast Media Market Worldwide (2013): Percentage Breakdown of Sales for Bayer Schering Pharmaceuticals, Bracco, Covidien/Mallinckrodt, GE Healthcare, and Others (includes corresponding Graph/Chart)
    • Table 17: Radiopharmaceutical Contrast Media Market Worldwide (2009): Percentage Breakdown of Sales for GE Healthcare, Bristol-Myers Squibb, Covidien/Mallinckrodt, MDS Nordion and Others (includes corresponding Graph/Chart)

5. GLOBAL MEDICAL IMAGING MARKET - AN OVERVIEW

  • Medical Imaging - Changing the Landscape of Clinical Diagnosis
    • Table 18: Global Medical Imaging Equipment Installed Base (2013): Percentage Share Breakdown of Volume Installations for X-ray, Ultrasound, Magnetic Resonance, Computed Tomography, and Nuclear Medicine/PET by Country/Region (includes corresponding Graph/Chart)
  • Comparison of Modalities by Various Imaging Systems
    • Table 19: Cost Comparison of Different Imaging Modalities
  • Medical Imaging Industry under the Impact of Economic Downturn
  • Archaic X-Ray Imaging Modalities Paving Way for Digital X-Rays
  • Ultrasound Holds its Fort in the Medical Imaging Market
  • Technological Advancements Favor MRI Market
    • Table 20: Global MRI Usage by Application Area (2012) (includes corresponding Graph/Chart)
  • Comparison of MRI against Other Imaging Modalities
  • Nuclear Medicine Imaging Equipment Presents Lucrative Growth Opportunities
    • Table 21: Worldwide Installed Base of Nuclear Imaging Devices by Modality (2013) Percentage Share Breakdown of Number of Installations for SPECT and PET (includes corresponding Graph/Chart)
  • Hybrid Imaging to Herald a New Era of Diagnosis
  • Hybrid PET/MRI Systems: A New Fusion
    • Price Sensitivity & Competition from Alternatives Limit Market Potential
    • Unfounded Fears of Radiation Exposure Hinder Growth
    • Bottlenecks in Developing Markets
  • Use of Contrast Agents in Other Imaging Modalities
  • Fluoroscopy
  • Computed Tomography
  • Future Growth Prospects for Medical Imaging Equipment Market

6. PRODUCT OVERVIEW

  • Contrast Agents
  • Contrast Media: How Do They Function
    • Where Are They Used...
  • Evolution of Contrast Media: A Profile
    • Bismuth Nitrate: Beginning of Contrast Agents
  • Imaging Agents: Significant Developments in the Last Fifty Years
  • Schering Develops First Intravenous Contrast Agent
  • MRI: Creating a New Era for Contrast Agents
  • A Peek into the Finer Points of Differences Among Contrast Media
  • Second Generation Non-Ionic Contrast Agents: An Introduction
  • Choice of the Contrast Medium: A Weighty Decision
  • Factors affecting choice of Imaging Agents
  • Taxonomy
  • Types of Contrast Media
  • X-Ray Contrast Medium
    • Table 22: Comparative Analysis of Structure of Non-ionic and ionic X-ray Contrast Media
  • MRI Contrast Medium
    • Role of Contrast Enhancement in MR Angiography (MRA)
    • MRI Contrast Agents for the Liver
  • Ultrasound Contrast Medium
    • Ultrasonographic Contrast Media: What Are They
    • Ultrasound Contrast Enhancement in Cardiology
    • Functionalities of Vascular Ultrasound Contrast Agents
  • Diagnostic Radiopharmaceuticals
    • A Delineate of Diagnostic Radiopharmaceuticals
    • Diagnostic Radiopharmaceuticals: A Technical Run-Through
    • Applications
    • Classification
      • Cardiology Diagnostics
      • Non-cardiology Diagnostics
      • Molecular Imaging Modalities in Radiopharmaceutical Diagnostics
      • Planar Imaging
      • Positron Emission Tomography (PET)
      • Applications of PET
      • Commonly used Radioisotopes in PET Scans
      • Major PET Isotopes and their Applications
      • Single Photon Emission Computed Tomography (SPECT)
      • Applications of SPECT
      • Commonly used Radioisotopes in SPECT Scans

7. TECHNOLOGY DYNAMICS

  • Proprietary Technologies Making In-Roads
  • Advanced Magnetics' Proprietary Colloidal Superparamagnetic Particle Technology
  • Enzon's Single Chain Antigen-Binding Technology
  • Immunomedics' Antibody Technology
  • NeoRx's "Painting the Target" Technology
  • Gas Encapsulation Technology for Ultrasound Contrast Media
  • Pharmacyclics' Texaphyrin Technology
  • Regulatory Bodies
  • Entry Barriers
  • Research Driven Markets
  • Highly Competitive Market
  • Economies of Scale
  • Substitutes in Agents Manufacturing
  • New X-ray Diagnostic Agents
  • Amide-based Macrocyclic Ligands - Potential MRI Agents
  • Gadolinium (III) Complexes - Potential MRI Contrast Agents
  • Metal-Containing Compounds Act As Potential Contrast Agents
    • Therapeutic Applications
    • Diagnostic Applications
  • Magnetic Gels as Potential MRI Contrast Agents
  • PFCs as Diagnostic Contrast Agents
  • Saline Flushes To Help Ensure Accurate Delivery of Contrast Agents

8. PRODUCT LAUNCHES/APPROVALS/ CLINICAL TRIALS

  • GE Introduces Vizamyl Alzheimer's imaging Agent
  • Navidea Biopharmaceuticals Obtains FDA Approval for Lymphoseek Injection for New Indication
  • Bayer Obtain FDA Approval for Gadavist for Breast Cancer Evaluation
  • GE Healthcare Gets Norwegian Medicines Agency Approval for Sonazoid™ to Detect Focal Liver Lesions
  • ImaginAb Announces Initial Phase I/IIa Results for 89Zr-Df-IAB2M Prostate Imaging Agent
  • Primal Imaging Receives FDA Approval for Neuraceq PET Imaging Agent
  • NanoHybrids Introduces Premium Product Line of Imaging Contrast Agents
  • CMC Contrast AB Obtains Orphan Drug Designation from the US FDA for CMC-001
  • GE Healthcare Obtains FDA Approval for its Oslo Plant to Manufacture Optison Heart Imaging Agent
  • GE Healthcare Gets FDA Approval for Vizamyl Alzheimer's Imaging Agent
  • GeccoDots Launches New Contrast Agent
  • Navidea Biopharmaceuticals Signs Agreement with Nordion
  • Navidea Biopharmaceuticals Launches Lymphoseek®
  • GE Healthcare Gets Expanded FDA Approval for AdreView
  • Guerbet Obtains FDA Approval for Dotarem MRI Contrast Agent
  • PerkinElmer Introduces GFR-Vivo 680
  • Navidea Obtains FDA Approval for Lymphoseek® Injection
  • Navidea Signs Agreement with Maimonides Medical Center to Collaborate on Clinical Trial Utilizing Lymphoseek® Injection in Colorectal Cancer
  • Molecular Insight Pharmaceuticals Commences Phase II Clinical Trial with Prostate Cancer Molecular Imaging Agent
  • Navidea Launches Phase II Clinical Trial with NAV4694
  • FDA Approves Production and Use of Choline C 11 Injection to Detect Recurrent Prostate Cancer
  • PerkinElmer Introduces HER2Sense™ Preclinical Imaging Agent

9. RECENT INDUSTRY ACTIVITY

  • ImaginAb and Duke-NUS Partner to Develop in vivo Molecular Imaging Agents
  • AC Immune and Piramal Imaging Strike Deal to Develop Alzheimer's Imaging Agent
  • Blue Earth Diagnostics Commences Operations
  • Enlyton Bags SBIR Contract from NCI for Pre-Clinical Development of Tumor Imaging Agent
  • Guerbet Obtains FDA Approval for Lipiodol Contrast Agent Manufacturing Plant
  • Integrated Diagnostics Launches InDi Molecular
  • Endocyte Signs Licensing Agreement with Endocyte for etarfolatide Cancer Diagnostic Imaging Agent
  • Siemens' PETNET Solutions Signs Agreement with Navidea Biopharmaceuticals
  • Covidien to Spin-Off Mallinckrodt
  • Eli Lilly to Acquire two Alzheimer's Imaging Agents from Siemens
  • Siemens PETNET Solutions Expands Manufacturing and Distribution of Amyvid
  • Jazz Pharmaceuticals Acquires EUSA Pharma

10. FOCUS ON SELECT PLAYERS

  • Bayer Healthcare Pharmaceuticals (Germany)
  • Bracco Diagnostics, Inc. (US)
  • Daiichi Sankyo Company Limited (Japan)
  • Eisai Co., Ltd. (Japan)
  • Eli Lilly and Company (US)
  • EUSA Pharma (Europe) Ltd. (UK)
  • GE Healthcare (UK)
  • Guerbet Group (France)
  • Lantheus Medical Imaging Inc (US)
  • Mallinckrodt Pharmaceuticals (Ireland)

11. GLOBAL MARKET PERSPECTIVE

    • Table 23: World Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 24: World Historic Review for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 25: World 15-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 26: World Recent Past, Current & Future Analysis for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 27: World Historic Review for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 28: World 15-Year Perspective for Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 29: World Recent Past, Current & Future Analysis for Contrast Media by Product Segment - X-Ray, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 30: World Historic Review for Contrast Media by Product Segment - X-Ray, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 31: World 15-Year Perspective for Contrast Media by Product Segment - Percentage Breakdown of Dollar Sales for X-Ray, MRI and Ultrasound Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 32: World Recent Past, Current & Future Analysis for X-Ray Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 33: World Historic Review for X-ray Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 34: World 15-Year Perspective for X-Ray Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 35: World Recent Past, Current & Future Analysis for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 36: World Historic Review for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 37: World 15-Year Perspective for MRI Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 38: World Recent Past, Current & Future Analysis for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 39: World Historic Review for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 40: World 15-Year Perspective for Ultrasound Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 41: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 42: World Historic Review for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 43: World 15-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Contrast Media Market to Witness Slow but Steady Growth
    • Table 44: US Contrast Media Market by Leading Players (2013): Percentage Dollar Share Breakdown for Bayer, Bracco, GE Healthcare, Mallinckrodt and Others (includes corresponding Graph/Chart)
    • Diagnostic Radiopharmaceuticals to Drive Future Growth
    • Table 45: The US Diagnostic Radiopharmaceutical Agents Market (2012): Percentage Share Breakdown of Procedure Volume by Imaging Procedure - SPECT and PET (includes corresponding Graph/Chart)
    • Table 46: US Market for Diagnostic Radiopharmaceuticals Agents (2012): Percentage Share Breakdown of Value Sales for Cardiology and Non-Cardiology Applications (includes corresponding Graph/Chart)
    • Table 47: US Market for Cardiology Diagnostic Radiopharmaceuticals (2010): Percentage Share Breakdown of SPECT Myocardial Perfusion Imaging (MPI) Procedure Volume by Imaging Agent - Cardiolite, Myoview, Thallium, and Sestamibi (includes corresponding Graph/Chart)
    • Recession Impact in Retrospect
    • Growth Stimulants in a Nut Shell
    • Demographic Changes Offer Growth Opportunities
    • Table 48: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Dynamics of Pricing
    • Key Trends and Issues
      • Expanding Applications to Stimulate Growth in Dx Radiopharmaceuticals Market
      • New Oncology, Neurology Agents to Boost Growth
    • Table 49: US Market for Non-Cardiology Diagnostic Radiopharmaceuticals Agents (2012): Percentage Share Breakdown of Value Sales for Oncology and Non-Oncology Applications (includes corresponding Graph/Chart)
      • Managing Alzheimer's Opens New Avenues for Imaging Agents
      • List of FDA Approved Alzheimer's Diagnostic Imaging Agents
      • Alzheimer's Stats
    • Table 50: Alzheimer's Prevalence in the US: As a Percentage of Population by Age-Group (includes corresponding Graph/Chart)
    • Table 51: Alzheimer's Prevalence in the US by State: 2014 & 2025 (includes corresponding Graph/Chart)
      • Nuclear Cardiology Products Drive Diagnostic Radiopharmaceuticals Market
      • Cardiovascular Imaging to Lead Volume Growth
      • PET Procedures in the US on Rise
    • Table 52: US PET Market by Leading Players (2013): Percentage Market Share Breakdown of Value Sales for GE Healthcare, Philips Healthcare, Siemens Healthcare and Others (includes corresponding Graph/Chart)
      • Growing Adoption of SPECT/CT
      • Rising Incidence of Cancer - A Major Growth Driver
    • Table 53: US Cancer Fatalities by Gender (2014): Percentage Share Breakdown of No. of Deaths for Men and Women (includes corresponding Graph/Chart)
    • Table 54: New Cancer Cases by Gender and Affected Site in the US (2013)
      • Isotope Shortage Leads to Dependence on Imports
      • DOE's Flawed Isotope Program Adds to the Woe
      • US Fluorodeoxyglucose (FDG) Market: An Overview
    • Table 55: US FDG Market by Procedure Type (2012): Percentage Share Breakdown of Procedure Volume for Oncology, Neurology, and Cardiology (includes corresponding Graph/Chart)
    • Competitive Analysis - Imaging Market
      • Reimbursement Issues
      • Medicare Payment Settings for Contrast Agents and Radiopharmaceuticals
      • Contrast Agents and Diagnostic Radiopharmaceuticals Bundled As Supplies
      • Implications of Reimbursement Changes
      • Magnetic Resonance Imaging
      • CMS' Rules Change Cuts Down Technical Component of MRI Reimbursement
    • Table 56: A Comparison of Medicare Reimbursement Rates for Upper and Lower Extremity MRI Examinations for 2012 and 2013
    • Table 57: MRI Reimbursement Changes: CPT Codes for MRI and MR Angiography (MRA) and Payment Rates for 2013 and 2014
      • The Fallout of ATRA on MRI Examination Trends
    • Regulatory Environment
      • Provisions Regarding Off-Label Usage of Contrast Media
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 58: US Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 59: US Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 60: US 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current and Future Analysis
      • An Overview of Medical Imaging Market
    • Table 61: Percentage Distribution of Canadian Population by Age Group: 2012 (includes corresponding Graph/Chart)
      • Canadian Scientists Discover Remedy for Isotope Shortages
      • Regulatory and Legal Restrictions
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 62: Canadian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 63: Canadian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 64: Canadian 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
      • Demographics Drive Market Growth
    • Table 65: Japanese Population by Age Group (2012) (includes corresponding Graph/Chart)
    • Table 66: Japanese 65+ Years Population: 1950-2010 (includes corresponding Graph/Chart)
      • Number of Nuclear Medicine Procedures on the Rise
      • Reimbursement Issues
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 67: Japanese Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 68: Japanese Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 69: Japanese 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Outlook
    • Debt Crisis in Europe Affects Healthcare Industry
    • European Healthcare System: In a State of Transition
    • Nuclear Medicine Imaging Equipment Market: An Overview
    • Table 70: European Installed Base for Diagnostic Imaging Equipment by Modality (2013): Percentage Share Breakdown of Volume Installations for SPECT, PET/CT, SPECT/CT, Planar, Cardiac SPECT, and PET/MR (includes corresponding Graph/Chart)
    • Cancer: A Major Driver for Diagnostic Radiopharmaceuticals
    • Table 71: Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart)
    • Ageing Demography - An Opportunity Indicator
    • Table 72: Population Breakup by Age Group for Select European Countries: 2011 (as a Percentage of Total Population) (includes corresponding Graph/Chart)
    • Reimbursement
    • Outsourcing of Imaging Diagnostics
      • Distribution Structure
      • Direct Sales
      • License Agreements
      • Distribution Agreements
      • A Price Sensitive Market
    • Macro Environment
      • Germany
      • France
      • Spain & Italy
      • Scandinavia
  • B. Market Analytics
    • Table 73: European Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 74: European Historic Review for Imaging Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 75: European 15-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 76: European Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 77: European Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 78: European 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current and Future Analysis
    • Growth Stimulants
    • Guerbet Group - A Key Player
  • B. Market Analytics
    • Table 79: French Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 80: French Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 81: French 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current and Future Analysis
    • Bayer Healthcare Pharmaceuticals - A Key Player
  • B. Market Analytics
    • Table 82: German Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 83: German Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 84: German 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Current and Future Analysis
  • B. Market Analytics
    • Table 85: Italian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 86: Italian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 87: Italian 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 88: UK Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 89: UK Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 90: UK 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Current and Future Analysis
  • B. Market Analytics
    • Table 91: Spanish Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 92: Spanish Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 93: Spanish 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4f. RUSSIA

  • A. Market Analysis
    • Current and Future Analysis
  • B. Market Analytics
    • Table 94: Russian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 95: Russian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 96: Russian 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Product Approval
    • Strategic Corporate Developments
    • Mallinckrodt Pharmaceuticals (Ireland) - A Key Player
  • B. Market Analytics
    • Table 97: Rest of Europe Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 98: Rest of Europe Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 99: Rest of Europe 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
    • Healthcare Spending in Asia-Pacific: On the Rise
    • Aging Populace - Potential Opportunities
    • Table 100: Over 65 Years Individuals as % of Total Population in Select Asian Countries (includes corresponding Graph/Chart)
    • India & China Offer Significant Growth Opportunities
    • MRI Market in Asia
  • B. Market Analytics
    • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 102: Asia-Pacific Historic Review for Imaging Agents by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 103: Asia-Pacific 15-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 105: Asia-Pacific Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 106: Asia-Pacific 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • Current and Future Analysis
    • Medical Imaging Equipment Market - An Overview
    • Increasing Expenditure on Healthcare Sector
  • B. Market Analytics
    • Table 107: Chinese Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 108: Chinese Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 109: Chinese 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5b. INDIA

  • A. Market Analysis
    • India - A High Potential Market
    • Regulatory Mechanism for Guiding Isotope Production and Distribution
    • Overview of CT Scanners Market in India
    • PET/CT Scanning in India Gathers Momentum
    • J.B.Chemicals and Pharmaceuticals Ltd - A Key Player
  • B. Market Analytics
    • Table 110: Indian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 111: Indian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 112: Indian 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
      • Korea
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 113: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 114: Rest of Asia-Pacific Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 115: Rest of Asia-Pacific 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

6. THE MIDDLE EAST

  • A. Market Analysis
    • Current and Future Analysis
  • B. Market Analytics
    • Table 116: Middle East Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 117: Middle East Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 118: Middle East 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

7. LATIN AMERICA

  • A. Market Analysis
    • Current and Future Analysis
    • Private Sector Boosts Healthcare Segment
  • B. Market Analytics
    • Table 119: Latin American Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 120: Latin American Historic Review for Imaging Agents by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 121: Latin American 15-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin American Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 122: Latin American Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 123: Latin American Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 124: Latin American 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

7a. BRAZIL

  • A. Market Analysis
    • Current and Future Analysis
  • B. Market Analytics
    • Table 125: Brazilian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 126: Brazilian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 127: Brazilian 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

7b. REST OF LATIN AMERICA

  • A. Market Analysis
    • Current and Future Analysis
  • B. Market Analytics
    • Table 128: Rest of Latin America Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 129: Rest of Latin America Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 130: Rest of Latin America 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top